Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

320.67
+1.660.52%
Post-market: 320.670.00000.00%19:30 EDT
Volume:168.28K
Turnover:53.83M
Market Cap:19.40B
PE:34.81
High:320.81
Open:320.04
Low:319.00
Close:319.01
52wk High:330.75
52wk Low:263.00
Shares:60.49M
Float Shares:60.49M
Volume Ratio:0.59
T/O Rate:0.28%
Dividend:4.63
Dividend Rate:1.44%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.98
PE(LYR):7.73

Loading ...

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Oct 09

Exchange-Traded Funds, Equity Futures Up Pre-Bell Friday as Oil Prices Fall, Traders Assess SpaceX Spectrum Deal

MT Newswires Live
·
Oct 09

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Oct 09

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Oct 09

UnitedHealth price target lowered to $402 from $430 at TD Cowen

TIPRANKS
·
Oct 09

U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines

Reuters
·
Oct 09

Piper Sandler recommends buying UnitedHealth on 2027 Star Ratings release

TIPRANKS
·
Oct 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 09

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Oct 09

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Oct 09

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Oct 09

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Oct 09

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Oct 09

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

GlobeNewswire
·
Oct 09

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Oct 09

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Oct 09

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Oct 09

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Oct 09

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Oct 09

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Oct 09